| FDA-approved small-molecule kinase inhibitors P Wu, TE Nielsen, MH Clausen Trends in pharmacological sciences 36 (7), 422-439, 2015 | 1102 | 2015 |
| Small-molecule kinase inhibitors: an analysis of FDA-approved drugs P Wu, TE Nielsen, MH Clausen Drug discovery today 21 (1), 5-10, 2016 | 536 | 2016 |
| Reactivity and synthetic applications of multicomponent Petasis reactions P Wu, M Givskov, TE Nielsen Chemical Reviews 119 (20), 11245-11290, 2019 | 225 | 2019 |
| Allosteric small-molecule kinase inhibitors P Wu, MH Clausen, TE Nielsen Pharmacology & therapeutics 156, 59-68, 2015 | 218 | 2015 |
| Scaffold Diversity from N-Acyliminium Ions P Wu, TE Nielsen Chemical reviews 117 (12), 7811-7856, 2017 | 194 | 2017 |
| A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9 B Maji, SA Gangopadhyay, M Lee, M Shi, P Wu, R Heler, B Mok, D Lim, ... Cell 177 (4), 1067-1079. e19, 2019 | 178 | 2019 |
| PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress P Wu, YZ Hu Current medicinal chemistry 17 (35), 4326-4341, 2010 | 115 | 2010 |
| Phosphorylation-inducing chimeric small molecules SU Siriwardena, DNP Munkanatta Godage, VM Shoba, S Lai, M Shi, ... Journal of the American Chemical Society 142 (33), 14052-14057, 2020 | 112 | 2020 |
| Inhibition of RNA-binding proteins with small molecules P Wu Nature Reviews Chemistry 4 (9), 441-458, 2020 | 101 | 2020 |
| Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities W Huang, L Tang, Y Shi, S Huang, L Xu, R Sheng, P Wu, J Li, N Zhou, ... Bioorganic & medicinal chemistry 19 (23), 7158-7167, 2011 | 85 | 2011 |
| Small molecules targeting phosphoinositide 3-kinases P Wu, Y Hu MedChemComm 3 (11), 1337-1355, 2012 | 75 | 2012 |
| Dual-target-directed 1, 3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer’s disease W Huang, D Lv, H Yu, R Sheng, SC Kim, P Wu, K Luo, J Li, Y Hu Bioorganic & medicinal chemistry 18 (15), 5610-5615, 2010 | 66 | 2010 |
| Clinical and marketed proteasome inhibitors for cancer treatment J Zhang, P Wu, Y Hu Current medicinal chemistry 20 (20), 2537-2551, 2013 | 58 | 2013 |
| PI3K inhibitors for cancer therapy: what has been achieved so far? P Wu, T Liu, Y Hu Current medicinal chemistry 16 (8), 916-930, 2009 | 54 | 2009 |
| Synthesis, biological evaluation and quantitative structure-activities relationship of flavonoids as vasorelaxant agents X Dong, T Liu, J Yan, P Wu, J Chen, Y Hu Bioorganic & medicinal chemistry 17 (2), 716-726, 2009 | 52 | 2009 |
| Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl) quinoxalines as PI3Kα inhibitors P Wu, Y Su, X Liu, L Zhang, Y Ye, J Xu, S Weng, Y Li, T Liu, S Huang, ... European journal of medicinal chemistry 46 (11), 5540-5548, 2011 | 40 | 2011 |
| Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors X Lv, H Ying, X Ma, N Qiu, P Wu, B Yang, Y Hu European Journal of Medicinal Chemistry 99, 36-50, 2015 | 39 | 2015 |
| Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein–RNA Interaction of LIN28 and Let-7 L Borgelt, F Li, P Hommen, P Lampe, J Hwang, GL Goebel, S Sievers, ... ACS medicinal chemistry letters 12 (6), 893-898, 2021 | 36 | 2021 |
| Flavonoids as vasorelaxant agents: synthesis, biological evaluation and quantitative structure activities relationship (QSAR) studies X Dong, Y Wang, T Liu, P Wu, J Gao, J Xu, B Yang, Y Hu Molecules 16 (10), 8257-8272, 2011 | 30 | 2011 |
| Discovery of novel 2-piperidinol-3-(arylsulfonyl) quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors P Wu, Y Su, X Liu, B Yang, Q He, Y Hu Bioorganic & medicinal chemistry 20 (9), 2837-2844, 2012 | 26 | 2012 |
